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Patients
The inclusion criteria comprised age of 0-18 years and a diagnosis between 1 January 1993 and 31 December 2011 of de novo AML or MDS with t(6;9)/DEK-NUP214, as determined by G-, Q-, or R-banding, fluorescence in situ hybridization (FISH) and/or reverse transcription polymerase chain reaction (RT-PCR).
The study was conducted within the I-BFM study group cooperation and 24 study groups and treatment centers participated. They contributed background data for frequency analysis and submitted clinical and genetic data on 62 patients in the study: The Spanish Pediatric Hematology Society (SHOP; Spain, n=1), the Taiwan Pediatric Oncology Group (TPOG; Taiwan, n=3), the Technologies, Breda, The Netherlands) and stored at -80°C. Isolation of total cellular RNA was performed as described before. 3 The integrity of total RNA was checked using the Agilent 2100
Bio-analyzer (Agilent, Santa Clara, CA, USA). cDNA and biotinylated cRNA were synthesized, hybridized, and processed on the Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's guidelines as previously described. Gene expression profiling (GEP) was performed on 297 pediatric AML patient samples including eight t(6;9)-positive samples. The GEP data on the full cohort have been previously published but an individual analysis of t(6;9)/DEK-NUP214 was not yet performed. 4 Original data are available in the Gene Expression Omnibus repository (http://www.ncbi.nlm.nih.gov/geo; accession GSE17855). The gene expression profiles of t(6;9)-positive cases were compared with those of other representative pediatric AML samples. 4 Top scoring differentially expressed genes were presented in a top-list rated according to significance based on log-fold change and number of positive probe sets.
Quantitative real time PCR (RT-qPCR)
From the top-list of differentially expressed genes generated from the GEP, four genes were selected for further mRNA expression validation by RT-qPCR based on statistical significance, occurrence of multiple probes in the top-list, and log-fold change, combined with potential biological relevance; EYA3 (eyes absent homolog 3, Drosophila), SESN1 (sestrin 1), PRDM2, also known as RIZ (PR domain containing 2, with ZNF domain), and HIST2H4 (histone cluster 2, H4).
RT-qPCR was performed on t(6;9)/DEK-NUP214-positive samples from 17 patients (eight from the GEP profiled subset and nine additional available samples with acceptable quality from the included patients) and one cell line (FKH-1) and compared with AML without t(6;9)/DEK-NUP214
(31 patient samples and 13 cell lines). The ABI PRISM 7900HT sequence detector (Applied Biosystems, Foster City, CA, USA) was used. The primers applied are described in Supplementary   Table S1 . SYBRgreen dye was used to detect PCR products in the expression analysis of target genes. The expression of the genes was compared with that of the reference gene GAPDH, with primers and probe as previously described (Supplementary Table S1 ). 5 The average cycle threshold (Ct) value was used to calculate mRNA expression levels of target genes relative to the expression level of GAPDH using the comparative Cycle time (!Ct) method. 
FLT3-ITD detection
FLT3-ITD analysis was performed by PCR as previously described (Primer sequences are shown in the Supplementary Table S1 ) 7,8 on submitted t(6;9) cases with unknown FLT3-ITD status and available material. After electrophoresis on 1% agarose gel the samples were sequenced for presence of ITD.
Statistical analyses
The Kaplan-Meier method was used to estimate the 5-year probabilities of OS (pOS) and the 5-year event-free survival (pEFS). The 5-year cumulative incidence of relapse (pCIR) was calculated by the method of Kalbfleisch and Prentice. 9 The survival estimates were compared using the log- 
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